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Abstract
Background: Interferon-a/ribavirin combination therapy might promote hepatitis B surface antigen (HBsAg) seroclearance
in patients dually infected with hepatitis B and C viruses (HBV/HCV), but the long-term effect remains unclear. We aimed to
investigate the rate of and the factors associated with HBsAg seroclearance during long-term follow-up after interferon-a/
ribavirin combination therapy in HBV/HCV dually-infected patients.
Methodology/Principal Findings: Eighty-one patients who received interferon-a/ribavirin combination therapy for 24
weeks with a follow-up period of .24 weeks were enrolled. HBV serological markers and HBV DNA were determined every 6
months. Early and late HBsAg seroclearance were defined as HBsAg loss in less or more than 6 months after end-of-
treatment, respectively. Fifteen (18.5%) patients had HBsAg seroclearance during a mean follow-up period of 3.4 (0.5–5.1)
years. The 5-year cumulative incidence was 25.6%. Baseline cirrhosis and HBV DNA negativity 1 year after end-of-treatment
were independently predictive of HBsAg seroclearance with an odds ratio (OR), 95% confidence intervals (CI) of 16.6, 1.8–
153 and 9.2, 1.4–62.1, respectively, by Cox regression hazard analysis. Four patients developed early and 11 developed late
HBsAg seroclearance, respectively. Cox regression hazard analysis showed no factor was associated with early HBsAg
seroclearance, whilst HBV DNA negativity 1 year after end-of-treatment was the only significant factor predicting late HBsAg
loss (OR, 43.0; CI, 2.5–745). Five patients had HBsAg seroconversion with a 5-year cumulative incidence of 8.3%. HBV DNA
negativity at baseline and one year after EOT had a trend for HBsAg seroconversion. HCV response did not correlate to
HBsAg loss.
Conclusions: We demonstrated that interferon-a/ribavirin had long-term effect on HBsAg seroclearance in dually HBV/HCV-
infected patients. Baseline cirrhosis and seroclearance of HBV DNA 1 year after end-of-treatment were significant factors
associated with HBsAg seroclearance.
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Introduction
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are
the two leading causes of chronic liver disease, liver cirrhosis (LC), and
hepatocellular carcinoma (HCC) [1,2]. Since both viruses share the
same transmission routes, dual HBV/HCV infection is not uncom-
mon, accounting for 10–40% of patients with chronic hepatitis in
Taiwan and Europe [3,4]. Previous studies also indicated that HBV/
HCV dually infected patients had a much higher risk of developing
LC or HCC than those with HBV or HCV infection alone [5,6]
Seroclearance of hepatitis B surface antigen (HBsAg) is a rare
event in chronic hepatitis B (CHB) patients [7,8]. The estimated
annual incidence of HBsAg seroclearance is 0.1–2.26% [9,10]. A
recent study demonstrated the annual HBsAg seroclearance rate
has quite differed in Hepatitis B e antigen (HBeAg) positive and
negative populations (0.39 versus 2.61 per 100 person-years,
P,0.001) [10]. HBsAg seroclearance usually confers a favorable
outcome and is the optimal treatment goal. However, HBsAg
seroclearance is very rarely observed in HBV infected patients
receiving current antiviral agents, with an annual rate of 2.4–3.2%
with interferon (IFN) or pegylated IFN therapy and only ,1%
with nucleoside/nucleotide analogues [11,12]
IFN is an antiviral agent approved for the treatment of CHB
and chronic hepatitis C. Although IFN monotherapy has been
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introduction of ribavirin in combination with IFN-a or pegylated
IFN-a for HBV/HCV dually infected patients has been shown to
be as effective for patients with HCV monoinfection in terms of
sustained eradication of HCV viremia [14,15]. Interestingly, the
combination therapy could also promote HBsAg seroclearance in
HBV/HCV dually infected patients, which can reach 11.2% 6
months after end of treatment [16,17,18,19,20]. Recently, an
increased rate of HBsAg clearance to 8.7% was observed in
patients with HBeAg-negative chronic hepatitis B after 3 years of
peginterferon alpha-2a as a first-line treatment [21]. Whether the
rate of HBsAg loss among HBV/HCV dually infected patient
increases overtime after IFN plus ribavirin combination therapy
has not been well established. We conducted a long-term follow-up
study to explore the cumulative rate of and predictive factors
associated with HBsAg seroclearance in HBV/HCV dually
infected patients after IFN plus ribavirin combination therapy.
Materials and Methods
Patients
The present study is based on three previous studies investigating
the efficacy of IFN-a/ribavirin combination therapy in HBV/HCV
dually infected patients [16,17,18]. From April 1999 to April 2002,
102 patients with dual HBV/HCV infections were enrolled into the
three studies. All the patients were seropositive for HCV antibody
(anti-HCV) and HBsAg for more than 6 months. Except three
patients, alltheothers were positivefor serum HCVRNA(detectby
a standardized qualitative polymerase chain reaction (PCR) assay
(Cobas Amplicor HCV Monitor Version 2.0; Roche Diagnostics,
Branchburg, NJ, USA; detection limit 50 IU/ml)). Patients with
human immunodeficiency virus or hepatitis delta virus infection,
autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholan-
gitis, Wilson’s disease, a1-antitrypsin deficiency, decompensated
cirrhosis, overt hepatic failure, a current or past history of alcohol
Table 1. Baseline and follow-up data.
Baseline data
Male, n (%) 56 (69.1)
Mean age (years), mean 6 SD 46.4611.8
Post-treatment follow-up period, year, mean 6 SD (range) 3.761.2 (0.5–4.9)
Baseline ALT level (U/L), mean 6 SD 112.9677.8
Liver cirrhosis, n (%) 7 (8.6)
Positive HBeAg, n (%) 4 (4.9)
Baseline HBV DNA negativity, n (%) 34 (42)
Baseline HCV RNA level (log IU/ml), mean 6 SD 5.561.4
Follow-up data
Achievement of an HCV SVR, n (%) 59 (72.8)
HBV DNA negativity at EOT, n (%) 47 (58)
HBV DNA negativity 6 months after EOT, n (%) 36 (44.4)
HBV DNA negativity 1 year after EOT, n/N (%) 26/65 (40)
SD, standard deviation; ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; SVR, sustained virologic response; EOT,
end of treatment.
doi:10.1371/journal.pone.0020752.t001
Figure 1. 5-year cumulative probability of HBsAg seroclearance (a) and seroconversion (b) in HBV/HCV dually infected patients.
Fifteen patients had HBsAg seroclearance during the follow-up period with a 5-year cumulative incidence of 25.6% (a). HBsAg seroconversion was
found in 5 of the 81 patients. The 5-year cumulative incidence was 8.3% (b). HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C
virus.
doi:10.1371/journal.pone.0020752.g001
HBsAg Seroclearance in HBV/HCV Dual Infection
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evidence of HCC were excluded.
All patients received a regimen of 3–6 MU IFN-a thrice weekly
plus ribavirin 800–1200 mg per-day for 24 weeks. Of the 102
patients, 81 who were followed up more than 24 weeks after end of
treatment (EOT) were enrolled into the present long-term follow-
up study. During the follow-up period, liver function tests, HBV
serological markers and HBV DNA were tested at an interval of 6
months. HBsAg, antibody to HBsAg (anti-HBs), hepatitis B e
antigen (HBeAg), antibody to HBeAg (anti-HBe), and anti-HCV
were detected with commercially available enzyme-linked immu-
nosorbent assay kits (Abbott Laboratories, North Chicago, IL,
USA) in each local laboratory unit. Serum HBV DNA was
determined by a standardized automated quantitative PCR assay
(Cobas Amplicor HBV Monitor; Roche Diagnostics; detection
limit 200 copies/ml). Serum HCV RNA levels were measured
using the branched DNA assay (VERSANT HCV-RNA 3.0.
Assay, Bayer Diagnostics, Emeryville, CA, USA; quantification
limit 615 IU/ml). The study was conducted according to the
guidelines of the Declaration of Helsinki, with the principles of
good clinical practice, and was approved by local ethics
committees for patient’s chart review and data analysis without
informed consent.
Study endpoint
The primary aim of the study was the loss of serum HBsAg in
HBV/HCV dually infected patients after IFN-a/ribavirin combi-
nation therapy. The secondary aim was to evaluate the factors
related to HBsAg loss.
Definitions
HCV sustained virological response (SVR) was defined as
undetectable HCV RNA at 24 weeks after EOT. We defined early
HBsAg seroclearance as HBsAg loss within 6 months after EOT
and late HBsAg seroclearance as HBsAg loss beyond 6 months
after EOT. HBsAg seroconversion was defined as HBsAg loss and
seropositive anti-HBs.
Statistical analysis
Means and standard deviations were used to describe the
distribution of continuous variables. Independent t-tests were used
for comparing continuous variables. Chi-square and Fisher’s exact
test were used for comparing categorical variables. Cox propor-
tional hazards regression models were used to identify the
independent factors that might influence HBsAg seroclearance.
The cumulative probability of HBsAg seroclearance was analyzed
by the Kaplan-Meier actuarial curve method with the log-rank
test. All tests were two-sided, and a P value of ,0.05 was
considered statistically significant. All analyses were performed
using the SPSS 16.0 statistical package (SPSS, Inc., Chicago, IL,
USA).
Results
Patient demographics
Table 1 shows baseline and follow-up data of the 81 patients.
The mean post-treatment follow-up period was 3.461.1 (0.5–5.1)
years. Four (4.9%) patients were seropositive for HBeAg and 72
(88.9%) were seropositive for anti-HBe at baseline. Thirty-four
(42%) patients had undetectable HBV DNA at baseline. Baseline
HCV RNA level was 5.561.4 log IU/ml. Fifty-nine (72.8%)
patients achieved an HCV SVR after combination therapy.
During the follow-up period, 47 (58%), 36 (44.4%), and 26 (40%)
patients had undetectable HBV DNA at EOT and 6 and 12
months after EOT, respectively.
Cumulative probability and predictive factors of HBsAg
seroclearance
Fifteen patients had HBsAg seroclearance during the follow-up
period with a 5-year cumulative incidence of 25.6% (Figure 1a).
The annual incidence was 5.5% per person year. We analyzed
baseline and follow-up factors associated with HBsAg seroclear-
ance (Table 2). Baseline HBV DNA negativity (P=0.043) and
HBV DNA negativity 1 year after EOT (P=0.002) were
significantly positive factors associated with HBsAg seroclearance
Table 2. Comparison of baseline and follow-up factors in HBV/HCV dually infected patients who did versus did not achieve HBsAg
seroclearance.
HBsAg seroclearance P value
Yes No
Number of patients 15 66
Male, n (%) 10 (66.7) 46 (69.7) 1.000
Age (years) 51.569.2 45.2612.1 0.064
Posttreatment follow-up period, year, Mean6SD (range) 3.361.4 (0.5–4.5) 3.761.1 (0.5–4.9) 0.274
Baseline ALT level (U/L) 136.6678.3 107.5677.3 0.193
Liver cirrhosis, n (%) 3 (20) 4 (6.1) 0.114
Positive HBeAg, n (%) 0 (0) 4 (6.1) 1.000
Baseline HBV DNA negativity, n (%) 10 (66.7) 24 (36.4) 0.043
Baseline HCV RNA level (log IU/ml) 5.761.1 5.461.5 0.502
Achievement of an HCV SVR, n (%) 10 (66.7) 49 (74.2) 0.537
HBV DNA negativity EOT, n (%) 11 (73.3) 36 (54.5) 0.250
HBV DNA negativity 6 months after EOT, n (%) 9 (60) 27 (40.9) 0.251
HBV DNA negativity 1 year after EOT, n/N (%) 10/12 (83.3) 16/53 (30.2) 0.002
HBsAg, hepatitis B s antigen; SD, standard deviation; ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; SVR,
sustained virologic response; EOT, end of treatment.
doi:10.1371/journal.pone.0020752.t002
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PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e20752Figure 2. 5-year cumulative probability of HBsAg seroclearance was significantly associated with LC and HBV DNA. Using the Kaplan-
Meier method, the 5-year cumulative probability of HBsAg seroclearance was significantly associated with LC (P=0.007), baseline HBV DNA negativity
(P=0.012) and HBV DNA negativity 1 year after EOT (P=0.000). HBsAg, hepatitis B surface antigen; LC, liver cirrhosis; HBV, hepatitis B virus; EOT, end
of treatment.
doi:10.1371/journal.pone.0020752.g002
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PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e20752in univariate analysis. HBsAg seroclearance developed among
29.4% (10/34) of patients with baseline HBV DNA negativity and
38.5% (10/26) of patients with HBV DNA negativity 1 year after
EOT, which was significantly higher than the 10.6% (5/47)
among patients with baseline HBV DNA positivity (p=0.043) and
the 5.1% (2/39) among patients with HBV DNA positivity 1 year
after EOT (P=0.002), respectively. Baseline HCV RNA level and
HCV SVR achievement were not associated with HBsAg
seroclearance. Using the Kaplan-Meier method, we observed that
the cumulative probability of HBsAg seroclearance was signifi-
cantly associated with LC (P=0.007), baseline HBV DNA
negativity (P=0.012) and HBV DNA negativity 1 year after
EOT (P=0.000, Figure 2). In multivariate analysis by using Cox
regression hazard analysis, LC (P=0.013; odds ratio=16.6; 95%
CI=1.8–153.0) and HBV DNA negativity 1 year after EOT
(P=0.023; odds ratio=9.2; 95% CI=1.4–62.1) were the
independent factors associated with HBsAg seroclearance.
We also compare the long-term HBsAg seroclearance rate in
our conventional interferon group to our another cohort using
Pegylated-Interferon (Peg-IFN) in HBV/HCV co-infected pa-
tients. During 3.5 years post-treat follow up period, 12 of 69
patients had HBsAg seroclearance in our cohort and 12 of 36
patients had HBsAg seroclearance in Peg-IFN cohort. There is no
significant difference between the two groups (Chi-Square test, P
value=0.087).
Early and late HBsAg seroclearance
Of the 15 patients who achieved HBsAg seroclearance, 4
showed seroclearance in less than 6 months after EOT. In
univariate analysis, LC, baseline HBV DNA negativity and HBV
DNA negativity 6 months after EOT were significantly associated
with early HBsAg seroclearance (P=0.036, 0.028, 0.035, respec-
tively, Table 3). By using Kaplan-Meier method, the cumulative
probability of early HBsAg seroclearance remained significantly
associated with LC, HBV DNA negativity at baseline and 6
months after EOT (P=0.001, 0.016, 0.023, respectively, Figure 3).
Nevertheless, in multivariate analysis by using Cox regression
hazard analysis, no factor was independently associated with the
development of early HBsAg seroclearance.
Eleven of the remaining 77 patients achieved HBsAg seroclear-
ance beyond 6 months after EOT. In univariate analysis, HBV
DNA negativity 1 year after EOT was the only significant factor
related to late HBsAg seroclearance (P=0.001, Table 3). By using
Kaplan-Meier method, the cumulative probability of late HBsAg
seroclearance was significantly associated with HBV DNA
negativity 1 year after EOT (P=0.001, Figure 4). Cox regression
hazard analysis showed HBV DNA negativity 1 year after EOT
was the only significant factor related to late HBsAg seroclearance
(P=0.010; odds ratio=43.0; 95% CI=2.5–745).
Comparing the three cohort groups of early, late and non-
HBsAg loss, we found a trend of LC and baseline HBV DNA
negativity for the overall three groups (P=0.012, 0.011).
Cumulative probability and predictive factors of HBsAg
seroconversion
HBsAg seroconversion was found in 5 of the 81 patients. One
patient achieved seroconversion by 18 months, two by 24 months,
and two by 42 months after EOT. The 5-year cumulative
incidence was 8.3% (Figure 1b). The annual incidence was 1.8%
per person year. All five patients were HBeAg seronegative and
anti-HBe seropositive at baseline. Comparing the three groups of
HBsAg seroconversion, HBsAg seroclearance without seroconver-
sion and non-HBsAg seroclearance, there was a trend of baseline
HBV DNA negativity and HBV DNA negativity one year after
EOT (P=0.032, 0.004) (Table 4).
Discussion
Loss of HBsAg is the ultimate endpoint of antiviral therapy
for chronic HBV infection. It is accompanied by disease
remission in terms of ALT normalization and by a significantly
decreased risk of LC, hepatic failure, and HCC [22].
Table 3. Comparison of baseline and follow-up factors of HBV/HCV dually infected patients who did versus did not achieve early/
late HBsAg seroclearance.
Early HBsAg seroclearance P value Late HBsAg seroclearance P value
Yes No Yes No
Number of patients 4 77 11 66
Male, n (%) 2 (50) 54 (70.1) 0.583 8 (72.7) 46 (69.7) 1.000
Age (years) 56.067.3 45.9611.8 0.095 49.869.6 45.2612.1 0.234
Post-treatment follow-up period, year,
Mean6SD (range)
3.960.9
(2.5–4.5)
3.761.2
(0.5–4.9)
0.711 3.161.6
(1.0–4.5)
3.761.1
(0.5–4.9)
0.209
Baseline ALT level (U/L) 168.5664.2 110.0677.7 0.144 125.0682.4 107.5677.3 0.494
Liver cirrhosis, n (%) 2 (50) 5 (6.5) 0.036 1 (9.1) 4 (6.1) 0.548
Positive HBeAg, n (%) 0 (0) 4 (5.2) 1.000 0 (0) 4 (6.1) 1.000
Baseline HBV DNA negativity, n (%) 4 (100) 30 (39) 0.028 6 (54.5) 24 (36.4) 0.322
Baseline HCV RNA level (log IU/ml) 6.460.7 5.461.4 0.197 5.561.1 5.461.5 0.949
Achievement of an HCV SVR, n (%) 3 (75) 56 (72.7) 1.000 7 (63.6) 49 (74.2) 0.479
HBV DNA negativity EOT, n (%) 3 (75) 44 (57.1) 0.635 8 (72.7) 36 (54.5) 0.335
HBV DNA negativity 6 months after EOT, n (%) 4 (100) 32 (41.6) 0.035 5 (45.5) 27 (40.9) 1.000
HBV DNA negativity 1 year after EOT, n/N (%) 8/9 (88.9%) 16/53 (30.2) 0.001
HBsAg, hepatitis B s antigen; SD, standard deviation; ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; SVR,
sustained virologic response; EOT, end of treatment.
doi:10.1371/journal.pone.0020752.t003
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with an estimated annual incidence of 0.1% to 0.8% [9]. HBsAg
seroclearance is also observed in patients receiving treatment for
CHB including nucleoside/nucleotide analogues and IFN.
Several studies of lamivudine treatment reported absence or
less than 2% HBsAg seroclearance [23,24,25]. One-year
treatment with adefovir dipivoxil resulted in 1.6% HBsAg
seroclearance, and a recent studyu s i n gt e n o f o v i rd i s o p r o x i l
fumarate for 48 weeks resulted in 3% HBsAg seroclearance
[26]. Another study reported a 5% HBsAg seroclearance rate
after standard IFN-a treatment for 32 weeks [27]. A higher
HBsAg seroclearance rate of 7–11% was reported after 1-year
pegylated IFN treatment in patients with CHB monoinfection
[21,28].
Figure 3. Cumulative probability of early HBsAg seroclearance was significantly associated with LC and HBV DNA. Using Kaplan-Meier
method, the cumulative probability of early HBsAg seroclearance remained significantly associated with LC, HBV DNA negativity at baseline and 6
months after EOT (P=0.001, 0.016, 0.023). HBsAg, hepatitis B surface antigen; LC, liver cirrhosis; HBV, hepatitis B virus; EOT, end of treatment.
doi:10.1371/journal.pone.0020752.g003
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HCV interact with each other and affect immune responses.
Most dually infected cases have detectable levels of HCV
viremia and very low values of serum HBV DNA [29,30]. In
cases of HCV superinfection with HBV, HBsAg seroclearance
has been reported [31]. A large-scale prospective trial designed
to evaluate the efficacy of pegylated IFN-a-2a plus ribavirin
combination in HBV/HCV dually infected patients reported
11.2% HBsAg seroclearance [19]. The long-term data reported
here show that 25.6% of HBV/HCV dually infected patients
treated with IFN-a/ribavirin combination therapy achieved
HBsAg seroclearance during the 5-year follow-up period. This
higher rate of HBsAg seroclearance suggests that the viral
interaction between HBV and HCV may influence the rate of
HBsAg seroclearance.
Many factors are related to HBsAg seroclearance, including
HBV genotype. Yuen et al. reported that HBsAg carriers with
genotype B infection were more likely to clear HBsAg than those
with genotype C infection [22]. Others reported higher HBsAg
seroclearance in genotype A as compared to genotypes B, C, or D
after pegylated IFN-a treatment in HBeAg-positive patients
[21,28,32]. In HBe-negative patients, Marcellin et al. reported
that HBsAg seroclearance did not appear to be genotype related
[21]. In the present study, most of our patients were HBeAg-
Figure 4. Cumulative probability of late HBsAg seroclearance was significantly associated with HBV DNA. Using Kaplan-Meier method,
the cumulative probability of late HBsAg seroclearance was significantly associated with HBV DNA negativity 1 year after EOT (P=0.001). HBsAg,
hepatitis B surface antigen; HBV, hepatitis B virus; EOT, end of treatment.
doi:10.1371/journal.pone.0020752.g004
Table 4. Comparison of baseline and follow-up factors in HBV/HCV dually infected patients who did achieve HBsAg
seroconversion versus HBsAg seroclearance without seroconversion and non-HBsAg seroclearance.
HBsAg seroclearance with seroconversion
Non-HBsAg
seroclearance P value
Yes No
Number of patients 5 10 66
Male, n (%) 2 (40) 8 (80) 46 (69.7) 0.801
Age (years) 49.4610.4 52.569.0 45.2612.1 0.162
Posttreatment follow-up period, year, Mean6SD (range) 2.761.3 (1.5–4.5) 4.060.7 (2.5–4.5 3.761.1 (0.5–4.9) 0.071
Baseline ALT level (U/L) 81.4624.9 164.2682.0 107.5677.3 0.063
Liver cirrhosis, n (%) 1 (20) 2 (20) 4 (6.1) 0.100
Positive HBeAg, n (%) 0 (0) 0 (0) 4 (6.1) 0.354
Baseline HBV DNA negativity, n (%) 3 (60) 7 (70) 24 (36.4) 0.032
Baseline HCV RNA level (log IU/ml) 5.561.1 5.861.1 5.461.5 0.748
Achievement of an HCV SVR, n (%) 3 (60) 7 (70) 49 (74.2) 0.658
HBV DNA negativity EOT, n (%) 3 (60) 8 (80) 36 (54.5) 0.138
HBV DNA negativity 6 months after EOT, n (%) 4 (80) 5 (50) 27 (40.9) 0.344
HBV DNA negativity 1 year after EOT, n/N (%) 5/5 (100) 5/7 (71.4) 16/53(30.2) 0.004
HBsAg, hepatitis B s antigen; SD, standard deviation; ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; SVR,
sustained virologic response; EOT, end of treatment.
doi:10.1371/journal.pone.0020752.t004
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evaluated due to limited serum sample availability.
HBV DNA is another factor associated with HBsAg seroclear-
ance. Several studies reported that serum HBV DNA becomes
undetectable 1 to 2 years after HBsAg seroclearance [22,33]. In
the present study, HBV DNA negativity 1 year after EOT was the
most significant predictive factor of HBsAg seroclearance. We also
found a 53.3% 5-year cumulative incidence of HBsAg seroclear-
ance in patients with HBV DNA negativity 1 year after EOT. The
findings implied that HBsAg seroclearance might be promoted by
IFN/RBV in HBV/HCV dully-infected patients through the
achievement of HBV DNA seroclearance.
Interestingly, we found 35.5% of patients who had HBV DNA
negativity 6 months after EOT had reappearance of HBV DNA 1
year after EOT. The positive predictive value of HBsAg
seroclearance in patients with HBV DNA negativity 6 months
after EOT was only 25%. Using the corresponding SVR definition
of HCV is, therefore, not suitable for HBV response, and cannot
predict subsequent HBsAg seroclearance. Three of six (50%)
patients who had detectable HBV DNA 6 months after EOT and
became undetectable 1 year after EOT had HBsAg seroclearance
in the long-term follow-up period. Based on this result, HBV DNA
1 year after EOT, instead of 6 months after EOT, might be
recommended for predicting HBsAg seroclearance in clinical
settings.
We also observed that liver cirrhosis was another predictive
factor for HBsAg seroclearance. Increasing age has been
associated with HBsAg seroclearance [34,35]. In the current
study, HBsAg seroclearance rate in older patients tended to be
higher than that of their counterparts. A longer time period of
infection, an older age and a lower HBV DNA level are at risk of
cirrhosis and may largely contribute to this observation.
More recently, the low baseline levels of HBsAg was
demonstrated to be significantly associated with HBsAg clearance
6 months after antiviral therapy in patients dually infected with
HBV/HCV [20]. However, we did not quantify the levels of
HBsAg due to no serum sample available.
HBsAg seroconversion is not infrequent in Caucasian patients
undergoing IFN therapy [36], but is very rare in the Asian
population [37]. A recent study demonstrated a 3.5% HBsAg
seroconversion rate at 3 years post-treatment in HBeAg-negative
patients treated with pegylated IFN-a-2a [21]. In the present
study, the 5-year cumulative incidence of HBsAg seroconversion
was 8.3%. The fact that a substantially higher rate of HBsAg
seroconversion was found in our study as compared to studies of
CHB monoinfection suggests that HCV superinfection may
interact with HBV and enhance the appearance of anti-HBs after
loss of HBsAg [38,39].
In conclusion, we demonstrated that interferon-a/ribavirin had
long-term effects on HBsAg seroclearance in dually HBV/HCV
infected patients with a 5-year cumulative incidence of approx-
imately 25%. Baseline cirrhosis and HBV DNA seronegativity 1
year after EOT were significant factors predicting HBsAg
seroclearance. Those patients with sustained undetectable HBV
DNA after combination therapy had a higher probability of late
HBsAg seroclearance. The 5-year cumulative incidence of HBsAg
seroconversion was 8.3%. HBV DNA negativity at baseline and
one year after EOT had a trend for HBsAg seroconversion.
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